Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.

Exelixis’s Cabometyx continues to drive revenue growth, prompting a raised 2024 forecast to $2.15–$2.2 billion. Read my EXEL ...

Overall, the results with Keytruda are very similar to that seen ... for Opdivo in second-line HCC after it became clear the EMA would not accept the data that backed its US approval.

Keytruda is used to treat advanced melanona ... These are judgement calls; the MHRA will (rightly) want to exercise due diligence. The EMA launched its adaptive licensing (AL) pilot in March ...

Geron Corporation , a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Joseph Eid, M.D. as Executive Vice ...

(Nasdaq: EXEL) today reported financial results for the third quarter of 2024, provided an update on progress toward achieving key corporate objectives, and detailed its recent and anticipated ...

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...

ACCESSWIRE • last month EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.

Biologics with large markets, such as pembrolizumab (Keytruda), daratumumab (Darzalex ... For example, while a paper issued by the European Medicines Agency (EMA) in November 2023 that suggested that ...

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human ... a meeting examining the efficacy of three immunotherapies — Tevimbra, Merck's Keytruda (pembrolizumab), and ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...